Niclosamide Formulations for the Treatment of Influenza Infections
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 1R43AI167394-01
Grant search
Key facts
Disease
UnspecifiedStart & end year
20222023Known Financial Commitments (USD)
$298,479Funder
National Institutes of Health (NIH)Principal Investigator
PRESIDENT Gary FujiiResearch Location
United States of AmericaLead Research Institution
MOLECULAR EXPRESS, INC.Research Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Prophylactic use of treatments
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
Project Summary The principal goal of this project is to demonstrate that the FDA-approved anthelminthic drug, niclosamide, can be reformulated in a synthetic lung surfactant which can be aerosolized for the treatment of infections caused by respiratory viruses. The studies proposed in this SBIR Phase I application will be focused on testing this concept by suspending niclosamide loaded liposomes in our proprietary lung surfactant technology (Niclosurf) and testing candidate Niclosurf formulations in a mouse influenza challenge model. The effectiveness of Niclosurf as a treatment for respiratory viral infections caused by influenza will be evaluated.